Akebia Therapeutics ( NASDAQ:AKBA – Get Free Report ) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
A number of other brokerages have also recently issued reports on AKBA. Zacks Research upgraded shares of Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Leerink Partners lowered shares of Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price objective for the company. in a research note on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating on shares of Akebia Therapeutics in a report on Thursday, August 6th. Weiss Ratings cut shares of Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. Finally, Westpark Capital assumed coverage on shares of Akebia Therapeutics in a research report on Tuesday, September 8th. They set a “buy” rating and a $4.50 price target for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating ...